Effect of gallopamil on left ventricular function in regions with and without ischaemia

Stauch, M; Großmann, Georg; Schmidt, Ada C. Stefanescu; Richter, P; Waitzinger, J.; Wanjura, D; Adam, W. E.; König, Wolfgang

doi:10.1093/eurheartj/8.suppl_g.77

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sesto et al [14] observed an increase in enddiastolic volumes and a reduction in ejec tion fractions, though the differences were not statistically significant. Stauch et al [15], by using radionuclide ventriculography, after acute oral administration, observed no varia tions in enddiastolic volume, a reduction in ejection fractions at rest and an increase in ejection fractions during exercise. During chronic treatment, echocardiography is a use ful tool for assessing the drug influence on the left ventricular function, and the technique has been used for evaluating calcium antago nist drugs [ 16,17], During chronic treatment with gallopamil, Scrutinio et al [3] and Fisman et al [ 18] found no variations in ejection fractions and ventricular volumes in patients with a normal left ventricular function; the same result was obtained by Tartagni et al [19] using nuclear ventriculography.…”

Section: Discussionmentioning

confidence: 95%

Gallopamil in Chronic Stable Angina: Antianginal Effect and Mechanism of Action

Zanolla¹,

Carbonieri²,

Rossi³

et al. 1992

Cardiology

View full text Add to dashboard Cite

A double-blind, placebo-controlled, cross-over trial of oral gallopamil was performed in 10 patients with stable angina. Gallopamil significantly increased mean exercise time and 1-mm ST time. The rate-pressure product was increased at 1 -mm ST time, but unmodified at the highest comparable work load and at peak exercise. The ST segment depression was significantly reduced both at the highest comparable work load and at peak exercise. Gallopamil proves safe and effective; the mechanism of its anti-ischemic effect seems to be due both to an increase in myocardial oxygen supply and to a reduction in myocardial oxygen demand.

show abstract

Section: Discussionmentioning

confidence: 95%

Gallopamil in Chronic Stable Angina: Antianginal Effect and Mechanism of Action

Zanolla¹,

Carbonieri²,

Rossi³

et al. 1992

Cardiology

View full text Add to dashboard Cite

show abstract

“…17-22]. reduces peripheral arterial resistance, cardiac work and oxygen consumption [23][24][25][26]. In addition, gal lopamil dilates the epicardial coronary artery [27,28], decreases the excitability of the sinus node, delays atrio ventricular conduction (17,29], leads to a prolongation of the diastole and thus improves total myocardial perfusion [30].…”

Section: Discussionmentioning

confidence: 99%

Effect of Gallopamil on Myocardial Microperfusion in Patients with Stable Effort Angina: A Randomized, Cross-Over, Double-Blind, Placebo-Controlled Trial

et al. 1997

View full text Add to dashboard Cite

We evaluated the efficacy and safety of daily administration of gallopamil 150 mg/day and its effects on myocardial perfusion in a medium-term, randomized, double-blind, cross-over, placebo-controlled trial. We studied 19 patients (17 males and 2 females; mean age 57 ± 6.8 years) with stable effort angina, angiographically documented coronary artery disease and reversible perfusion defects during exercise thallium-201 myocardial scintigraphy of at least one segment of the left ventricle. After 2 weeks of a single-blind placebo run-in period, during which each patient underwent at least 2 exercise tests and a 48-hour Holter ECG recording, all patients were treated with either placebo or gallopamil 50 mg t.i.d. for 28 days. At the end of this period, patients crossed over to the alternate regimen. This phase was double blind. After treatment with placebo or gallopamil, patients underwent exercise tests, 24-hour Holter ECG recording and thallium-201 myocardial scintigraphy. Weekly angina frequency and trinitroglycerin (TNT) consumption and safety were also evaluated. No patients dropped out of the study because of major side effects. The number of total ischemic and symptomatic events recorded at 24-hour ECG monitoring, weekly angina frequency and TNT consumption were significantly reduced during gallopamil treatment. After gallopamil administration, exercise duration significantly increased (run-in: 419 ± 116 s, placebo: 420 ± 118 s, gallopamil: 511 ± 144 s; p < 0.05), and ST segment depression was significantly reduced (run-in: -1.3 ± 0.3 mm, placebo: -1.3 ± 0.3 mm, gallopamil: -0.94 ± 0.68 mm; p < 0.01), while heart rate, systolic blood pressure and rate-pressure product were unchanged at rest, at submaximal and at peak exercise. Qualitative and quantitative evaluation of myocardial perfusion and the myocardial uptake percentage of thallium-201 in ischemic zones were significantly improved by gallopamil treatment. These findings demonstrate that gallopamil can improve myocardial perfusion and reduce myocardial oxygen consumption.

show abstract

Professor Martin Stauch

Steinacker

1996

The Physiology and Pathophysiology of Exercise Tolerance

View full text Add to dashboard Cite

Effect of gallopamil on left ventricular function in regions with and without ischaemia

Cited by 8 publications

References 0 publications

Gallopamil in Chronic Stable Angina: Antianginal Effect and Mechanism of Action

Gallopamil in Chronic Stable Angina: Antianginal Effect and Mechanism of Action

Effect of Gallopamil on Myocardial Microperfusion in Patients with Stable Effort Angina: A Randomized, Cross-Over, Double-Blind, Placebo-Controlled Trial

Professor Martin Stauch

Contact Info

Product

Resources

About